July 22, 2025
Advancements in the development of intravesical therapies targeting Fibroblast Growth Factor Receptor (FGFR) mutations represent a significant milestone in personalized medicine for bladder cancer. FGFR mutations occur frequently in bladder cancer patients and are particularly common in aggressive, treatment-resistant tumors. Current clinical trials involving FGFR inhibitors such as erdafitinib are investigating their intravesical administration, delivering medication directly into the bladder to achieve high local drug concentrations. Preliminary findings from these trials have been promising, demonstrating effective tumor reduction and manageable safety profiles in genetically selected patient populations. This targeted approach not only increases treatment precision but also minimizes systemic exposure and associated side effects, making therapies safer and more tolerable for patients. FGFR-targeted intravesical therapies could significantly improve clinical outcomes by offering tailored treatments based on specific molecular profiles, thus optimizing patient response and potentially revolutionizing how bladder cancer is managed clinically.
Citation: Scientific Archives, 2025. Available at: https://www.scientificarchives.com
Implication: FGFR inhibitors could pioneer precision medicine approaches in bladder cancer.